Juergen Wolf

Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Dong-Wan Kim, Ranee Mehra et al. · New England Journal of Medicine · 2014 · 1.5K citations

Medicine, Oncology, Pharmacology +14

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari et al. · The Lancet · 2017 · 1.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry

Oliver Gautschi, Julie Milia, Thomas Filleron et al. · Journal of Clinical Oncology · 2017 · 356 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With <i>KRAS</i>-Mutant Advanced Non–Small Cell Lung Cancer

Pasi A. Jänne, Michel M. van den Heuvel, Fabrice Barlési et al. · JAMA · 2017 · 332 citations · Full text

Medicine, Oncology, Pharmacology +17